1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Narcolepsy Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Narcolepsy Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Narcolepsy Market Regional Analysis
6.2 North America Narcolepsy Market Revenue 2016-2027 (US$ Million)
6.3 North America Narcolepsy Market Forecast Analysis
7. North America Narcolepsy Market Analysis – by Type
7.1 Narcolepsy with Cataplexy
- 7.1.1 Overview
- 7.1.2 Narcolepsy with Cataplexy: North America Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)
7.2 Narcolepsy without Cataplexy
- 7.2.1 Overview
- 7.2.2 Narcolepsy without Cataplexy: North America Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)
7.3 Secondary Narcolepsy
- 7.3.1 Overview
- 7.3.2 Secondary Narcolepsy: North America Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)
8. North America Narcolepsy Market Analysis – by Product
8.1 Central Nervous System Stimulants
- 8.1.1 Overview
- 8.1.2 Central Nervous System Stimulants: North America Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)
8.2 Sodium Oxybate
- 8.2.1 Overview
- 8.2.2 Sodium Oxybate: North America Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)
8.3 Antidepressants
- 8.3.1 Overview
- 8.3.2 Antidepressants: North America Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)
9. North America Narcolepsy Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: North America Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: North America Narcolepsy Market – Revenue and Forecast, 2016-2027 (US$ Million)
10. North America Narcolepsy Market – North America Analysis
10.1 Overview
10.2 North America
- 10.2.1 North America Narcolepsy Market Breakdown, by Key
Country, 2019 and 2027 (%)
- 10.2.1.1 North America Narcolepsy Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 US:
North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.1.1 US: North America Narcolepsy Market Breakdown, by Type
- 10.2.1.1.2 US: North America Narcolepsy Market Breakdown, by Product
- 10.2.1.1.3 US: North America Narcolepsy Market Breakdown, by Distribution Channel
- 10.2.1.2 Canada:
North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.2.1 Canada: North America Narcolepsy Market Breakdown, by Type
- 10.2.1.2.2 Canada: North America Narcolepsy Market Breakdown, by Product
- 10.2.1.2.3 Canada: North America Narcolepsy Market Breakdown, by Distribution Channel
- 10.2.1.3 Mexico :
North America Narcolepsy Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.3.1 Mexico : North America Narcolepsy Market Breakdown, by Type
- 10.2.1.3.2 Mexico : North America Narcolepsy Market Breakdown, by Product
- 10.2.1.3.3 Mexico : North America Narcolepsy Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Teva Pharmaceutical Industries Ltd.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Jazz Pharmaceuticals plc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Arena Pharmaceuticals, Inc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Graymark Healthcare, Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Novartis AG
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Takeda Pharmaceutical Company Limited
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Mylan N.V.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 BIOPROJET
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Shionogi & Co., Ltd.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Ligand Pharmaceuticals, Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For North America Narcolepsy Market
